Atomoxetine - Strattera brand: Discontinuation
Eli Lilly are discontinuing all strengths of their Strattera brand atomoxetine.
Affected product
Eli Lilly are discontinuing the following products:
Atomoxetine (Strattera brand)
- 10 mg caps - Pharmacode: 2181568
- 18 mg caps - Pharmacode: 2181576
- 40 mg caps - Pharmacode: 2181592
Atomoxetine listing in the Schedule(external link)
Alternative product
People can still access atomoxetine in all the same strengths. The Apo-Atomoxetine brand is already listed and remains available.
APO-Atomoxetine contains the same active ingredients in the same amounts as Strattera brand. It works in the body the same way. Medsafe have evaluated the product to ensure it meets standards of safety and quality. They have assessed that it works as well as Strattera.
This discontinuation is a global decision made by Eli Lilly.
Key dates
April 2023 – Strattera brand stock depleted.
1 November 2023 – Strattera brand will be de-listed from the Pharmaceutical Schedule.
Who to contact
If you have any questions about the funding of atomoxetine, email enquiry@pharmac.govt.nz